ReproCELL Inc. 4978
TSE · Japan · Health Technology
¥132.00-7.00 (-5.04%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine product Stemchymal®, for which the company holds exclusive commercialization rights in Japan. The application seeks approval for the use of Stemchymal® to suppress the progression of ataxia in patients with spinocerebellar ataxia (SCA3 and SCA6).
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Viral Vaccine Cell Culture Media Market size & share revenue was valued at approximately USD 1.9 Billion in 2025 and is expected to reach USD 2.1 Billion in 2026 and is expected to reach around USD 3.5 Billion by 2035, at a CAGR of 6.2% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Thermo Fisher Scien
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.